|
|
|
|
| LEADER |
02280nam a2200253 u 4500 |
| 001 |
EB002001738 |
| 003 |
EBX01000000000000001164639 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: Vedolizumab (Entyvio -- Takeda Canada Inc.)
|h Elektronische Ressource
|b indication : for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response to, or were intolerant to either conventional therapy or infliximab, a tNF[alpha] antagonist
|
| 246 |
3 |
1 |
|a Vedolizumab (Entyvio -- Takeda Canada Inc.)
|
| 250 |
|
|
|a Version: 1
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, May 2020
|
| 300 |
|
|
|a 1 PDF file (9 pages)
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 500 |
|
|
|a "Final."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK565293
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Vedolizumab is a humanized immunoglobulin G1 monoclonal antibody that binds exclusively to the alpha 4 beta 7 human integrin on pathogenic gut-homing lymphocytes, acting as a gut-selective anti-inflammatory biologic. The IV formulation has been approved by Health Canada for adults with moderately to severely active Crohn disease and for the treatment of adult patients with moderately to severely active UC who have had an inadequate response or loss of response to, or who were intolerant to either conventional therapy or infliximab, a TNF alpha antagonist. The SC injection formulation of vedolizumab is the current focus of this review. It is meant to be used in the maintenance phase of treatment at 108 mg every two weeks (vial with 108 mg/0.68 mL) after induction with the IV formulation. The Health Canada approved indication of the SC formulation is "for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response to, or were intolerant to either conventional therapy or infliximab, a TNF[alpha] antagonist."
|